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Background: The receptor tyrosine kinase Axl and its ligand growth arrest-specific protein 6 (Gas6) are involved in
the diabetic vascular disease. The aim of this study was to explore the role of Gas6/Axl system in high glucose
(HG)-induced endothelial dysfunction.
Methods: We investigated the effect of various glucose concentrations on Axl signaling in human microvascular
endothelial cells (HMEC-1 s).
Results: Human plasma Gas6 value inversely correlated with glucose status, endothelial markers. HG decreased
Gas6/Axl expression and increased intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1
(VCAM-1) expression in HMEC-1 s. HG significantly decreased HMEC-1 s cell viability and tube formation and promoted
monocyte-EC adhesion. Down-regulation of Akt phosphorylation was found in HG culture. Axl transfection significantly
reversed HG-induced Akt phosphorylation, VCAM-1 expression and endothelial dysfunction. We also found additive
changes in Axl-shRNA-infected HMEC-1 cells in HG culture. Furthermore, Axl overexpression in HMEC-1 s significantly
reversed HG-induced vascular endothelial growth factor (VEGF) and VEGF receptor 2 (VEGFR2) expression. In addition,
significantly lower Axl and VEGFR2 expression in arteries were found in diabetic patients as compared with
non-diabetic patients.
Conclusions: This study demonstrates that HG can alter Gas6/Axl signaling and may through Akt and VEGF/VEGFR2
downstream molecules and suggests that Gas6/Axl may involve in HG-induced EC dysfunction.
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Diabetes mellitus (DM) is a common metabolic disease
with a high and increasing prevalence worldwide. The
estimated number of patients afflicted with diabetes, pre-
sently about 170 million people, is expected to increase
and reach a pandemic rate of 366 million by the year 2030
[1]. The diabetic condition is characterized by and is re-
sponsible for alterations in micro- and macro-vascular
beds, by inducing changes in neovascular mechanisms
and impairing vascular homeostasis [2,3]. Dysfunction of* Correspondence: metahung@yahoo.com
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unless otherwise stated.the vascular endothelium is regarded as an important fac-
tor in the pathogenesis of micro- and macro-angiopathy
[4,5] and endothelial function has gained increasing atten-
tion in the study of vascular disease. Endothelial cell (EC)
injury and proliferative dysfunction are considered to be
the initial events in the development of atherosclerosis,
postangioplasty restenosis, plaque erosion, and throm-
boembolism, which are contributors to macro-vascular
complications [5]. Inhibition of the vascular endothelial
growth factor (VEGF)–VEGF receptor 2 (VEGFR2) sig-
naling axis may play a role in EC dysfunction and serious
vascular complications associated with diabetes [6]. How-
ever, the mechanisms by which diabetes-induced EC dys-
function occurs remain poorly identified.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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family of vitamin K-dependent coagulation proteins and is
recognized as a growth factor-like molecule, as it interacts
with receptor tyrosine kinases of the TAM (Tyro-3, Axl,
Mer) family [7]. The Gas6/TAM system regulates an
intriguing mix of processes, including cell survival and
proliferation, cell adhesion and migration, blood clot
stabilization, and inflammatory cytokine release. Hence,
the role of the Gas6/TAM system has been found to be
important in injury, repair, inflammation, hemostasis,
autoimmune disease, vascular systems, and cancer [8].
Over the years, numerous studies have identified the
pivotal role Gas6 plays in vascular biology and diseases
[9,10]. Gas6 and its receptors are involved in the patho-
genesis of neointima formation, vasculitis and atheros-
clerosis [11-14].
Recently, several reports revealed that the Gas6/TAM
system was involved in the pathogenesis of diabetic renal
and vascular disease. Expression of Gas6/TAM was in-
creased in the glomerulus of diabetic rats, which led to
mesangial and glomerular hypertrophy [15]. In vascular
smooth muscle cells, Gas6/Axl signaling increased cell
survival in the presence of low glucose (LG) and increased
cell migration in the presence of high glucose (HG) [16].
Our report also elucidates plasma Gas6 levels are asso-
ciated with altered glucose tolerance, inflammation, and
endothelial dysfunction. Plasma Gas6 concentration may
represent an independent risk factor of type 2 diabetes,
and a potential surrogate marker of inflammation and
endothelial dysfunction [17]. These studies indicate that
Gas6/TAM likely represents an important pathogenic
mechanism for renal and cardiovascular complications
associated with diabetes.
The sequence and nature of the antiapoptotic and
angiogenesis events resulting from Gas6/Axl interactions
have been most extensively studied in murine NIH-3 T3
fibroblasts and many different types of cancer [18-21]. In
this system, Gas6/Axl interactions activate Akt through
phosphorylation. Akt itself is a serine-threonine kinase
that has been shown to be a key intracellular regulator of
cellular survival. Activation of Akt leads to downstream
signaling events, including those associated with the mito-
chondrial regulation of apoptosis and angiogenesis [15].
Interestingly, the Gas6/Axl pathway can interact with
other growth factor signals, as has been shown for
VEGFR2 in EC morphogenesis [22]. However, the plau-
sible role of Gas6/Axl molecules and its downstream
signaling in the context of hyperglycemia and endothelial
dysfunction has never been explored. In the present study,
we demonstrate for the first time that HG causes
Gas6/Axl/Akt-dependent down regulation of VEGF and
VEGFR2 expression. Furthermore, a decrease in cell via-
bility and angiogenesis and increased vascular cell adhe-
sion molecule-1 (VCAM-1) production and induction ofmonocyte-endothelial cell adhesion in human microvascu-
lar endothelial cells (HMEC-1) are observed.
Methods
Cell culture
Immortalized HMEC-1 were maintained in medium
MCDB-131 (Sigma) supplemented with 15% FBS (GIBCO,
Carlsbad, CA), 10 ng/ml EGF (R&D Systems, Minneapolis,
MN), 1 μg/ml dsdahydrocortisone (Sigma, St. Louis, MO)
and 10 mM L-glutamin (GIBCO, Carlsbad, CA) at 37 in a
humidified 5% CO2 incubator. For high glucose, cells were
grown in 20 or 40 mmol/L glucose and controls received
20 or 40 mmol/L mannitol or 5 mmol/L glucose. Human
embryonic kidney cell line HEK293T were maintained in
medium DMEM (GIBCO, Carlsbad, CA) supplemented
with 10% FBS.
Transfection
Axl knockdown plasmids (TRCN575-sequense 5′CGAAA
TCCTCTATGTCAACAT and TRCN576-sequense 5′GC
TGTGAAGACGATGAAGATT) were purchased from
Academia Sinica RNAi core, Taiwan. Axl overexpression
plasmid was constructed in pCMV-Tag2A (pCMV-Tag2A/
Axl(s)). Axl cDNA was amplified by RT-PCR with sense
5′-CCCAAGCTTGGAAAGTTTGGCACCCATG-3′ and
antisense 5′-CCCAA GCTTGGTTGTCTCAGGCACC
ATC-3′. HMEC-1 cells were transfected with knockdown
or overexpression plasmid using lipofectamine™ 2000
transfection reagent according to the manufacturer’s in-
structions (Invitrogen). Knockdown assay was performed
with lent virus system and the protein expression was con-
firmed by western blot of Axl.
RNA extraction and RT-PCR
Cryogenic conditions were used for mRNA extraction,
which was performed following the protocol described for
the commercial reactive TripureR (Roche Applied Science,
Indianapolis, IN). The total RNA was extracted, purified,
and converted to cDNA using oligo d(T)12–18 primer to
preserve the relative mRNA profile and produce a tem-
plate suitable for the PCR. In the PCR step, 50 pmol each
of sense and antisense primers were used. The primer
sequences were the following: sense 5′-CCACATCGCT
CAGACACCAT-3′and antisense 5′-TGACCAGGCGCC
CAAT A-3′ for GAPDH and sense 5′-TGTCCTAG
CCTGTGTGTCAGTGA-3′ and antisense 5′-GGACCC
TGGTGGCTGTGCCCCCTGTC-3′ for Axl and sense
5′-GCATCA ACAAGTATGGGTCTCC′ and antisense
5′-CCCAAGTCCATCTCACTATTTAC AG-3′ for Gas6.
Standard PCR amplification conditions were applied, which
consisted of a hot start at 94°C for 5 minutes, followed by
94°C for 30 seconds, 55°C for 30 seconds, and 72°C for
1 minute for 30 cycles, with a final amplification at 72°C for
10 minutes. Each measurement was performed in duplicate,
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amplification curve. The geometric mean of the GAPDH
endogenous expression was used for the normalisation of
the expression.
Western blot
Western blotting was performed with a SDS-PAGE electro-
phoresis system. Briefly, protein samples were re-suspended
in sample buffer (containing 10% β-mercaptoethanol) and
electrophoresed on a 10% SDS-PAGE. Protein were trans-
ferred electrophoretically onto a polyvinylidene fluoride
(PVDF) membrane and nonspecific binding sites blocked
by immersion of membrane into 5% - milk. The mem-
brane was incubated with primary antibodies against Axl,
Gas6, ICAM-1, VCAM-1 and VEGFR2 (Santa Cruz, CA,
USA), p-Akt, Akt, p-44/42 MAPK, 44/42 MAPK (both
from Cell Signaling Technology, Danvers, MA) and
GAPDH antibody (Novus Biologicals, Littleton, CO) was
used as loading control. A horseradish peroxidase-conju-
gated mouse anti-goat, goat anti-mouse, goat anti-rabbit
antibody (purchased from Jackson, USA) was then added
as secondary antibody. Protein was detected by Luminata
Classico Western HRP Substrate (Millipore, Bedford,
MA). Semi-quantification of relative protein expression
was analyzed with Image J.
Cell viability assay
The influence of each concentration of HG to HMEC-1
was assessed by MTT assay. HMEC-1 were seeded at a
density of 5,000 and 10,000 cells/well in 96-well plates and
allowed to attach. Cells were treated with HG medium
(serum free) for 0, 1, 3, 5, and 7 days with MTT (Usb)
then added and survival determined. The data reported
represent the mean ± SD of each experiments performed
with 3 replicates tested.
Migration
HMEC-1 were seeded at a density 3 × 106 cells/well in 6
well plates and allowed to attach. After making a straight
scratch with a sterile 200 pipette tip, a wound was simu-
lated and cells were treated with high glucose medium
(serum free). Both wound edges were monitored and
recorded after 2, 4, 8, 12 h using the fluorescence mi-
croscopy (4 × magnification, OLYMPUS CKX41 coupled
with camera).
ELISA
The VEGF released by HMEC-1 in the culture medium
was quantified using a Human VEGF ELISA kit (R&D
Systems, Minneapolis, MN) according to the manu-
facturer’s instructions. The VEGF was measured in the
culture medium of the cells exposed to all experimental
conditions.Cell adhesion test
HMEC-1 cells (1 × 106 cells/ml) were cultured in normo-
glycemic (NG, 5 mmol/L glucose) and hyperglycemic (HG,
40 mmol/L glucose) of 6-well culture plate, Incubate the
cells for 24 h in CO2 incubator. The fluorescence labeling
of THP-1 with calcein-AM, incubate the cells (1 × 107
cells/ml) with 5 μ calcein-AM in RPMI 1640 for 30 min at
37°C in CO2 incubator. The cells were washed three times
with PBS to remove excess dye and resuspended in phenol
red-free RPMI 1640 (with 10% FBS) at a density of 1 × 106
cells/ml. After high glucose treat the HMEC-1 cell co-
cultured with calcein-AM labeled cells (1 × 106/ml, well) in
CO2 incubator at 37°C for 1 h. The HMEC-1 cell were
washed four times with PBS to remove the non-adherent
calcein-AM labeled cells and replaced with 1.0 ml of PBS.
The fluorescence of each well was measured using a fluo-
rescence microscopy with excitation and emission wave-
lengths of 480 nm and 530 nm, respectively.
Tube formation
BDMatrigel™ Basement Membrane Matrix (BD Biosciences,
San Jose, CA) was thawed overnight at 4°C and mixed to
homogeneity with condition medium without serum.
Culture plates (24 well) were coated with 0.3 mL of matri-
gel and allowed to gelatinize at 37°C for 3 hours. After
centrifugation, HMEC-1 cells (1 × 105) were resuspend in
high glucose medium and seeded in matrigel. The EC-
directed tube formation was monitored and recorded after
16–18 h of incubation using the fluorescence microscopy
(4 × magnification, OLYMPUS CKX41 coupled with cam-
era). The average length of tubes formed was counted in
five different fields in each of the three independent re-
peats and quantified by Image J.
Human samples
A total of 300 adults were recruited from the outpatient
clinics of Tri-Service General Hospital, Taipei, Taiwan.
Criteria for inclusion and exclusion into this study and
the analytic methods of clinical variables in this study
were the same as our previous study [17]. In addition,
ten patients undergoing coronary artery bypass grafting
(CABG) for documented coronary artery disease were
recruited for the present study. All patients undergoing
CABG surgery enrolled in this study were hemodynamic
stable patients and the operation was done in an elective
fashion. Discarded human left internal mammary artery
(LIMA) tissues were obtained from patients undergoing
CABG. The institutional review board of the Tri-Service
General Hospital approved the protocol and all subjects
provided written informed consent.
Frozen section and immunohistochemistry
Discarded human IMA were taken from the operation
room and placed immediately at −80°C. The snap frozen
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Biosystems, Nussloch, Germany) and equilibrate at −20°C
for frozen sectioning to 5 μm. Sections were air dried for
5 min and washed to remove OCT. For immunohisto-
chemical staining, each section was blocked with blocking
solution for 1 h and incubated for 15 minutes in 3%
H2O2 diluted in methanol, with complete washing of
sections between each steps. Specimens of LIMA were
stained with primary antibodies: rabbit polyclonal to Axl
(Abcam, #ab37861, Cambridge, UK,) and rabbit polyclonal
to VEGFR2 (#55B11, Cell Signaling Technology, Danvers,
MA) diluted in Dako diluent (Dako, #s3022, Dako Cyto-
mation, Glostrup, Sweden) for 1 h at room temperature
followed by detection with the Dako REAL EnVision sys-
tem (Dako, #K5007, Dako Diagnostics, Dublin, Ireland)
and mounted under cover slips.
Protein isolation from frozen/OCT-embedded samples
After excess OCT was washed with ddH2O and 1X PBS,
each tissue section was moved to a 2 ml tube containing
ceramic beads (2.8 mm, bertin technologies). Lysis buffer
(50 mM Tris–HCl [pH7.4], 150 mM NaCl, 2 mM EDTA,
1% NP-40, 0.1% SDS, protease inhibitor) was added, and
the sample was homogenized by vortexing and grinding in
a homogenizer (Precellys®24, bertin technologies, France).
The sample was kept on ice for 30 min to complete the
lysis reaction and centrifuged (4°C, 13000 g, 15 minutes)
for supernatant collection. Collected sample was stored
at −80°C.
Statistical analysis
Descriptive results of continuous variables were expressed
as means ± standard error of the mean (SE). We used
unpaired t test and ANOVA test for comparisons of quan-
titative variables. Relationships between variables were
tested using Spearman rank-order correlations and partial
correlation analysis after adjusting for age. Proliferation
data are means ± SE. Immunoblot data are means ± SD of
band intensity relative to control. All experiments were
repeated for n = 3–6. Groups are analyzed for differences
by one-way ANOVA followed by Tukey's test. Significance
was considered as being accepted at P < 0.05. All the sta-
tistical analyses were performed using the program SPSS
(Chicago, Illinois, USA; version 13.0).
Results
Human plasma Gas6 protein concentrations are
associated with glucose tolerance and endothelial
dysfunction
In our previous report [17], we demonstrated that plasma
Gas6 concentrations were significantly lower among pa-
tients with type 2 diabetes compared with subjects with
NGT as illustrated in Table 1. In all subjects as a whole,
the plasma Gas6 value was significantly and inverselycorrelated with glucose status and endothelial dysfunction
markers (Table 2). In addition, we evaluated the asso-
ciation between plasma Gas6 protein levels and corre-
sponding glucose values under acute glucose challenge
using oral glucose tolerance test (OGTT) in 104 type 2
diabetic patients. In Figure 1, the plasma Gas6 value was
significantly and inversely correlated with glucose levels
during OGTT (p for trend < 0.001).
HG concentrations and Gas6/Axl, ICAM-1 and VCAM-1
expression in HMEC-1 s
To determine whether HG affects Gas6/Axl, ICAM-1 and
VCAM-1 expression in ECs, HMEC-1 s were cultured in
5, 20 and 40 mM glucose and equimolar concentrations of
mannitol for 24 h. As compared to the HMEC-1 s in nor-
mal glucose, Gas6/Axl mRNA and Axl proteins expres-
sion were decreased by HG (Figure 2A,B). However, the
expression of endothelial functional markers, ICAM-1
and VCAM-1 proteins, were significantly increased at 20
and 40 mM glucose compared with 5 mM glucose in
HMEC-1 s. (Figure 2C). HMEC-1 s grown in mannitol did
not change in Gas6/Axl, ICAM-1 and VCAM-1 expres-
sion (Figure 2A-C). Therefore, the effect of D-glucose on
these proteins expression was not secondary to osmotic
load. These data showed that HG leads to a decrease in
Gas6/Axl mRNA and protein level in HMEC-1 s, which
likely contributes to endothelial dysfunction with in-
creased ICAM-1 and VCAM-1 proteins expression.
HG concentrations and HMEC-1 cell viability, adhesion,
tubule formation and migration
As summarized in Figure 3, HMEC-1 s were cultured
in HG and mannitol for endothelial function tests. In
Figure 3A, we measured the proportion of live HMEC-1
cells remaining after 72 h in the 5, 20 and 40 mM glucose
and equimolar concentrations of mannitol using the MTT
assay. HG significantly decreased HMEC-1 s survival with
dose-dependent but not mannitol. To investigate the role
of HG in HMEC-1 cell angiogenesis, we preformed the
tube formation assay. Figure 3B, illustrates that HG
elicited a dose-dependent decrease in tube formation. Sig-
nificant decreased tube formations were evident at 20 and
40 mM glucose but not mannitol. We then evaluated the
effect of HG in THP-1 (Human monocyte cell line) ad-
hesion to HMEC-1 by using the monocyte-EC adhesion
assay. As indicated by adhesion rate, HG promoted signifi-
cant monocyte-EC adhesion (Figure 3C). However, HG
and mannitol did not influence HMEC-1 cell migration
when cells were maintained in migration assay for 36 h
(Figure 3D).
HG concentrations and Akt expression in HMEC-1 s
In order to further evaluate the involvement of down-
stream signaling in HG-triggered HMEC-1 s, Akt and
Table 1 Anthropometric and biochemical variables among different glucose tolerance subjects
NGT IGT Type 2 Diabetes *P value
(n = 100) (n = 96) (n = 104)
Age (years) 51.3 ± 1.46 55.1 ± 1.35 53.8 ± 1.28 0.032
Sex (M/F) 45/55 36/60 59/45 0.005
Blood pressure (mmHg)
Systolic 119.4 ± 1.56 124.7 ± 1.69 126.8 ± 1.78 0.005‡
Diastolic 75.4 ± 0.82 77.6 ± 1.24 83.2 ± 1.13 0.006‡
OGTT glucose (mmol/L)
Fasting glucose 5.03 ± 0.08 5.48 ± 0.12 8.34 ± 0.38 <0.001‡
2 h glucose 6.30 ± 0.06 10.13 ± 0.11 17.1 ± 0.36 <0.001‡
HbA1C (%) 5.5 ± 0.02 6.1 ± 0.06 8.4 ± 0.13 <0.001
‡
HOMA-IR§ 2.02 ± 0.18 3.42 ± 0.22 4.89 ± 0.28 <0.001‡
Endothelial dysfunction markers
E-selectin (ng/ml) 44.8 ± 1.53 48.5 ± 1.82 62.3 ± 2.32 <0.001‡
VCAM-1 (ng/ml) 518.2 ± 32.12 514.2 ± 36.81 668.4 ± 39.23 0.005‡
ICAM-1 (ng/ml) 245.2 ± 8.78 246.2 ± 8.61 295.2 ± 9.52 <0.001‡
Gas6 (ng/ml)§ 15.2 ± 0.42 13.5 ± 0.48 11.2 ± 0.31 0.002‡
*assessed by one-way ANOVA, data shown as mean ± standard error mean.
§The logarithms of these variables were used for the analysis.
‡NGT vs. type 2 diabetes. All assessed by post-hoc LSD test.
NGT, normal glucose tolerance; IGT, impaired glucose tolerance; OGTT, oral glucose tolerance test; ICAM-1, intercellular adhesion molecule 1; VCAM-1, vascular cell
adhesion molecule 1.
A
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phosphorylated status of Akt and MAP kinase using the
anti–phospho-Akt and anti–phospho-MAP kinase anti-
body. In a time dependent manner, decreased Akt phos-
phorylation but no changes in MAP kinase were shown
0.5 to 12 hours after HG (40 mM D-glucose) treatment
(Figure 4A). In addition, down-regulation of Akt phos-
phorylation was noted after HG treatment with a dose
dependent manner, whereas no change was observed for
MAP kinase phosphorylation (Figure 4B). These dataTable 2 Age-adjusted Spearman partial correlation
coefficients between plasma Gas6 concentration and
biochemical variables
Spearman partial correlation coefficient*
All (n = 300)
r P
OGTT glucose (mmol/L)
Fasting glucose −0.186 0.002
2 h glucose −0.162 0.007
HbA1c (%) −0.158 0.029
E-selectin (ng/ml) −0.161 0.008
VCAM-1 (ng/ml) −0.282 <0.001



















Figure 1 Human plasma Gas6 protein concentrations are
associated with corresponding glucose levels during OGTT.
A total of 104 type 2 diabetic patients were collected and received
OGTT. (A) The plasma Gas6 value was significantly inversely correlated
with glucose levels during OGTT (p for trend < 0.001). (B) The plasma
Gas6 and glucose ratio showed significant reduced during OGTT
(p for trend < 0.001). Lower plasma levels of Gas6 tended to be
associated with higher plasma glucose levels.
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Figure 2 HG concentrations and Gas6/Axl, ICAM-1 and VCAM-1 expression in HMEC-1 s. HMEC-1 s were cultured in 5, 20 and 40 mM glucose
and equimolar concentrations of mannitol for 24 h. (A,B) Gas6/Axl mRNA and Axl proteins expression were decreased by HG. (C) The expressions of
ICAM-1 and VCAM-1 proteins were increased with a glucose dose-dependent manner. HMEC-1 s grown in mannitol did not change in Gas6/Axl,
ICAM-1 and VCAM-1 expression.
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volved in HG-induced HMEC-1 s dysfunction is Akt
signaling.
HG concentrations and Axl transfection in HMEC-1 s
The next aim of the investigation was to ascertain whe-
ther overexpression of Axl activity would affect the HG-
induced Akt phosphorylation, VCAM-1 expression and
cell dysfunctions in HMEC-1 s. To address this issue, cells
were transfected with an Axl over-expressed plasmid.
Transfection results revealed that the Axl transfection
significantly reversed HG-induced Akt phosphorylation
and VCAM-1 protein expression (Figure 5A) and in-
creased cell viability and tube formation (Figure 5B,C) and
decreased cell adhesion with monocytes (Figure 5D). The
control pcDNA3 transfection did not affect the HG-
induced responses and Axl transfection also did not af-
fect HG-induced MAP kinase phosphorylation (data not
shown).HG concentrations and Axl knockdown in HMEC-1 s
In order to confirm HG-induced Akt phosphorylation,
VCAM-1 expression and cell dysfunctions in HMEC-1 s
through Axl signaling, experiments were carried out to as-
sess whether Axl knockdown in HMEC-1 cells had additive
effect with HG-induced Akt phosphorylation, VCAM-1
expression and cell dysfunctions. The HMEC-1 s were
infected with Axl shRNA vectors and cultured in 5, 20 and
40 mM glucose and equimolar concentrations of mannitol.
We detected significant additive changes in the Akt phos-
phorylation, VCAM-1 expression, cell viability, tube forma-
tion and monocyte-EC adhesion of Axl-shRNA-infected
HMEC-1 cells in HG culture compared with HG alone
condition (Figure 6A-D). The control shRNA transfec-
tion did not affect the HG-induced responses and Axl
knockdown also did not affect HG-induced MAP kinase
phosphorylation (data not shown). The results sug-
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Figure 3 HG concentrations and HMEC-1 cell viability, adhesion, tubule formation and migration. (A,B) HG significantly decreased
HMEC-1 s survival and tube formation with dose-dependent manner. (C,D) HG promoted significant monocyte-EC adhesion but did not
influence HMEC-1 cell migration.
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HG-induced angiogenesis
Our results showed Axl was involved in HMEC-1 tube
formation and HG-induced angiogenesis. We further dis-
sected the mechanism of Axl regulation in HG-induced
tube formation and angiogenesis. In the previous reports
[21,23], Axl regulates processes vital for both neovascula-
rization and tumorigenesis in tumor cell and animal
models and was associated with expression of VEGF and
VEGFR2 angiogenic factors. We used Axl overexpression
and knockdown experiments in HMEC-1 cells to elucidate
the association of Axl and angiogenic factors (VEGF and
VEGFR2) expression. In Figure 7A and 7B, the results
revealed that the Axl overexpression in HMEC-1 s sig-
nificantly reversed HG-induced VEGF and VEGFR2 ex-
pression. Meanwhile, the Axl-shRNA-infected HMEC-1
cells showed significant additively decreased changes in
the HG (40 mM)-induced VEGF and VEGFR2 expression
(Figure 7C and D).Expression of Axl and VEGFR2 in artery from non-DM
and DM patients
In addition, we investigated the association between Axl
and VEGFR2 expression in HG-induced endothelial dys-
function, using the left internal mammary artery (LIMA)
collected from 10 patients (5 with diabetes and 5 without
diabetes) undergoing elective coronary artery bypass graft
(CABG). Expression of Axl and VEGFR2 in LIMA were
examined by western blot and immunohistochemical stai-
ning. As summarized in Figure 8, significantly lower Axl
and VEGFR2 expression were found in diabetic patients
as compared with non-diabetic patients (P = 0.003 and
P < 0.001, respectively). Furthermore, a significantly posi-
tive correlation between Axl and VEGFR2 expression in
LIMA was noted in diabetic patients (data not shown).
Discussion
In the present study, we dissected the role of Gas6/Axl and


































































Figure 4 HG concentrations and Akt expression in HMEC-1 s. (A) In a time dependent manner, decreased Akt phosphorylation but no
changes in MAP kinase were shown 0.5 to 12 hours after HG (40 mM D-glucose) treatment. (B) Down-regulation of Akt phosphorylation was
noted after HG treatment with a dose dependent manner, whereas no change was observed for MAP kinase phosphorylation.
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causes downregulation of Gas6/Axl through Akt signaling
to influence the expression of adhesion molecules and
VEGF/VEGFR2 in endothelial cell. These findings are sup-
ported by functional studies showing that a decrease of cell
viability and angiogenesis and induction of monocyte-EC
adhesion in HMEC-1 s under HG. While we manipulate
the Axl expression in HG cultured HMEC-1 s, they can be
through Akt signaling and modulate adhesion molecules
and VEGF/VEGFR2 then regulate endothelial adhesion
and angiogenic functions.
Interestingly, situations potentially associated with the
vascular homeostasis either in vitro cell study or in vivo
animal model, as for instance changes in pH, hydrogen
peroxide, inorganic phosphate, hypertension and athero-
sclerosis, all seem to be affected by Axl and/or Gas6 ex-
pression but the influence were inconsistent [16,24-26].
Axl is activated by hydrogen peroxide, which is increased
in vascular injury in both vascular smooth muscle cells
(VSMCs) and ex vivo vessels [27]. However, recent studies
have demonstrated that the inorganic phosphate-induced
VSMC apoptosis and subsequent calcification are de-
pendent on the down-regulation of the Gas6/Axl/Akt
survival pathway that inhibits apoptosis and increases sur-
vival of VSMCs [28,29]. Several reports suggest a role for
Axl in the pathogenesis of diabetic renal and vascular dis-
eases. Expression of Axl and Gas6 are increased in glo-
merulus of diabetic rats and HG stimulation of mesangial
cells, followed by induction and activation of Gas6/Axland the Akt/mTOR pathway, which leads to mesangial
and glomerular hypertrophy [15]. Cavet et al. [16] investi-
gated the effects of various glucose concentrations on Axl
signaling in VSMCs and demonstrated a role for glucose
in altering Axl signaling through coupling to binding part-
ners. The Axl receptor tyrosine kinase signaling system is
now emerging as an important regulator of mammalian
physiology and pathology with distinct and diverse mecha-
nisms of action, depending on the cell type or organ sys-
tem involved [30]. With the exception of VSMCs, there
was prospective evidence linking endothelial dysfunction
with atherosclerosis and demonstrating that endothelial
dysfunction was the first step in the atherosclerosis.
Endothelial dysfunction contributes to diabetic vascular
diseases, including hypertension, atherosclerosis, and co-
ronary heart disease, which are also characterized by insu-
lin resistance [31]. Also, ECs cultured in HG show delayed
replication, abnormal cell cycling, and increased apoptosis.
However, the mechanisms by which diabetes-induced
endothelial dysfunction remain poorly identified. In this
study, we first confirmed plasma Gas6 molecules are
inversely associated with glucose values and endothelial
dysfunction markers in human. Furthermore, we used
in vitro human EC model to elucidate HG, indeed, can re-
sult in down-regulation of Gas6/Axl signaling then cause
endothelial dysfunction with decrease of cell viability and
angiogenesis and induction of monocyte-EC adhesion
might be through suppressing VEGF/VEGFR2 expression
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Figure 5 HG concentrations and Axl transfection in HMEC-1 s. The Axl transfection significantly reversed HG-induced Akt phosphorylation
and VCAM-1 protein expression (A) and increased cell viability and tube formation (B,C) and decreased cell adhesion with monocytes (D).
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http://www.cardiab.com/content/13/1/53PI3K and Akt are downstream effectors of insulin sig-
naling, as well as important signaling molecules in the
regulation of glycogen metabolism in myocytes, lipocytes,
and hepatocytes [31]. However, PI3K/Akt also plays an
important role in EC functions by regulating angiogenesis,
proliferation, microvascular permeability, survival and
cellular transformation [32]. Recent study had shown
hyperglycemia-impaired PI3K/Akt signaling may promote
EC dysfunction in diabetes [33]. Previous reports have
shown that Gas6 appears to regulate endothelial activation
at least in part by binding its cognate tyrosine kinase re-
ceptor Axl [11]. This is not unexpected as various groups
found that Gas6 exerts effects on ECs via Axl and Akt-
dependent pathways [34]. In VSMC in vitro model, Cavet
et al. demonstrate that glucose modulates Axl signaling
via different cell signaling mechanisms. In HG, Gas6/Axl
stimulation increased ERK1/2 activation whereas Gas6/
Axl stimulated PI3K/Akt/mTOR in LG. Furthermore,Gas6/Axl signaling increased cell survival in LG and in-
creased migration in HG. However, the role of Gas6/Axl
and downstream signaling in the context of hyperglycemia
and endothelial functions has not been explored. Our
results showed evidence that hyperglycemia can cause
endothelial dysfunction with down-regulation of Gas6/Axl
signaling. Meanwhile, its effect was through Akt signaling,
but was not involved in MAP kinase signaling. After over-
expression of Axl, we can find reverse the effect of its
downstream signaling and EC functions. Moreover, while
using loss of function with Axl knockdown, there were
further impairments to its downstream signaling and cell
functions. Activation of Axl and its intracellular signaling
pathways PI3K/Akt has been shown to play a crucial role
in HG-induced EC viability and angiogenesis.
Diabetes is associated with abnormal angiogenesis.
The effect of HG on angiogenesis is often presented as a
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Figure 6 HG concentrations and Axl knockdown in HMEC-1 s. The HMEC-1 s were infected with Axl shRNA vectors and cultured in 5, 20 and
40 mM glucose and equimolar concentrations of mannitol. The results revealed significant additive changes in the Akt phosphorylation, VCAM-1
expression (A), cell viability (B), tube formation (C) and monocyte-EC adhesion (D) of Axl-shRNA-infected HMEC-1 cells in HG culture compared with
HG alone condition.
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http://www.cardiab.com/content/13/1/53late phase of diabetic retinopathy, defective angiogenesis
has been observed in different models such as wound
healing [35] and embryonic growth [36]. In diabetic pa-
tients and in rodent models of diabetes, collateral vessel
development, in response to coronary vessel occlusion has
been shown to be impaired by HG [32]. Angiogenic
response to tissue ischemia via hypoxia-inducible tran-
scription factors (HIF-1α and -2α), triggers a coordinated
response of angiogenesis and arteriogenesis by inducing
the expression of growth factors, such as the VEGF, the
angiopoietins, and the transforming growth factor-β1
(TGF-β1). A few animal models have shown that HG
affects VEGF/VEGF receptor signaling pathways, causing
the arrest of vascular development with regards to on-
going physiological angiogenesis [37]. It is also becoming
apparent that Gas6/Axl can further influence cell functionby modulating Wnt, VEGF, and integrin-mediated signaling
[22,38,39]; as such, signaling-independent mechanisms have
even been suggested [40]. Previous reports revealed that
cross talk between Gas6/Axl and VEGFR2 and Axl stimula-
tion by Gas6 resulted in inhibition of the ligand-dependent
activation of VEGFR2 and the consequent activation of an
angiogenic program in vascular ECs [22]. Our results are in
agreement with previous reports that HG reduced VEGF/
VEGFR2 and Gas6/Axl expression. We demonstrated that
Axl overexpression in HMEC-1 s significantly reversed
HG-induced VEGF/VEGFR2 expression. Meanwhile, the
Axl knockdown in HMEC-1 cells showed significant addi-
tive decreased changes in the HG-induced VEGF/VEGFR2
expression. Furthermore, we also found higher Axl and
VEGFR2 expression on LIMA tissue in non-diabetic
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Figure 7 Axl modulates expression of angiogenic factors in HG-induced angiogenesis. The results revealed that the Axl overexpression in
HMEC-1 s significantly reversed HG-induced VEGF and VEGFR2 expression (A and B). The Axl-shRNA-infected HMEC-1 cells showed significant
additively decreased changes in the HG (40 mM)-induced VEGF and VEGFR2 expression (C and D).
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http://www.cardiab.com/content/13/1/53diabetic patients, a significant association between Axl and
VEGFR2 expression in LIMA was noted. To the best of our
knowledge, our results are the first to confirm that HG can
influence on EC tube formation and angiogenesis by modu-
lating Gas6/Axl and VEGF/VEGFR2 signaling.A
B
Figure 8 Representative immunostaining and protein
expression of Axl and VEGFR2 in DM and non-DM patients in
LIMA. DM patients showed lower expression of Axl and VEGFR2
compared with non-DM patients in immunostaining (A) and Western
blot results (B) (P = 0.003 and P < 0.001, respectively).Conclusions
In conclusion, the results of our study demonstrate that
exposure to increasing concentrations of glucose results
in altering EC viability, angiogenesis and adhesion func-
tions through Gas6/Axl/Akt signaling. If Gas6/Axl/Akt
signaling defects contribute to diabetic vascular com-
plications, then therapeutic restoration of activity may
have clinical significance. We suggest that upregulation
of Axl and Akt signaling pathways within the endothe-
lium should be considered as a target for future thera-
peutic modalities in protecting diabetic patients from
vascular complications.
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